Hsbc Holdings PLC Sells 6,202 Shares of iRadimed Corporation $IRMD

Hsbc Holdings PLC decreased its position in shares of iRadimed Corporation (NASDAQ:IRMD) by 28.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,357 shares of the medical equipment provider’s stock after selling 6,202 shares during the period. Hsbc Holdings PLC’s holdings in iRadimed were worth $1,469,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in IRMD. Quarry LP purchased a new position in shares of iRadimed in the 3rd quarter worth about $40,000. Farther Finance Advisors LLC increased its position in shares of iRadimed by 827.1% during the 4th quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 397 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 495 shares in the last quarter. CWM LLC lifted its position in iRadimed by 19.5% in the 4th quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock worth $64,000 after buying an additional 107 shares during the last quarter. Finally, USA Financial Formulas bought a new stake in iRadimed in the 4th quarter worth approximately $82,000. Institutional investors own 92.34% of the company’s stock.

iRadimed Stock Up 0.6%

NASDAQ IRMD opened at $95.08 on Tuesday. The company has a 50-day simple moving average of $94.29 and a two-hundred day simple moving average of $95.82. iRadimed Corporation has a 12-month low of $56.15 and a 12-month high of $107.90. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of 51.96 and a beta of 0.90.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings data on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.03. The firm had revenue of $21.98 million for the quarter, compared to analysts’ expectations of $21.32 million. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Equities analysts expect that iRadimed Corporation will post 1.52 earnings per share for the current fiscal year.

iRadimed Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, May 29th. Investors of record on Friday, May 15th were given a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.8%. The ex-dividend date was Friday, May 15th. iRadimed’s dividend payout ratio (DPR) is presently 43.72%.

Insider Transactions at iRadimed

In other iRadimed news, CEO Roger E. Susi sold 5,000 shares of iRadimed stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $87.51, for a total value of $437,550.00. Following the transaction, the chief executive officer directly owned 2,175,000 shares of the company’s stock, valued at $190,334,250. The trade was a 0.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 21,250 shares of company stock worth $1,836,403. 34.60% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have issued reports on IRMD. Weiss Ratings lowered iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, May 20th. Freedom Capital raised shares of iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $120.00.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.